Viking Therapeutics, Inc. (VKTX) DCF Valuation

Viking Therapeutics, Inc. (VKTX) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Viking Therapeutics, Inc. (VKTX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Viking Therapeutics, Inc. (VKTX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Optimice su tiempo y mejore la precisión con nuestra calculadora DCF (VKTX)! Utilizando datos reales de Viking Therapeutics, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y evaluar (VKTX) como un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -25.4 -42.7 -55.4 -70.4 -100.8 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .3 .3 .3 .3 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -25.6 -42.9 -55.7 -70.6 -100.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 275.6 248.4 202.1 155.5 362.1 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.4 4.0 1.4 8.5 7.5 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -25.6 -39.2 -54.7 -69.1 -100.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.9 -37.4 -56.9 -61.7 -101.8 -7.5 .0 .0 .0 .0
WACC, % 9.14 9.14 9.14 9.14 9.14 9.14 9.14 9.14 9.14 9.14
PV UFCF
SUM PV UFCF -6.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -7
Net Debt -54
Equity Value 47
Diluted Shares Outstanding, MM 94
Equity Value Per Share 0.50

What You Will Get

  • Real Viking Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Viking Therapeutics, Inc. (VKTX).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Viking Therapeutics' fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to Viking Therapeutics, Inc. (VKTX).
  • Time-Saving and Accurate: Eliminate the hassle of building models from scratch while ensuring precision and flexibility.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Viking Therapeutics, Inc. (VKTX).
  • WACC Calculator: Includes a pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to VKTX.
  • Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates relevant to Viking Therapeutics.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Viking Therapeutics, Inc. (VKTX).
  • Interactive Dashboard and Charts: Visual outputs present key valuation metrics for straightforward analysis.

How It Works

  • Download: Obtain the comprehensive Excel file featuring Viking Therapeutics, Inc. (VKTX) financial data.
  • Customize: Modify projections, including revenue growth, EBITDA %, and WACC to fit your analysis.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time for accurate insights.
  • Test Scenarios: Develop various projections and instantly compare different outcomes.
  • Make Decisions: Leverage the valuation results to inform your investment strategy with Viking Therapeutics, Inc. (VKTX).

Why Choose This Calculator?

  • User-Friendly Interface: Perfect for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your analytical needs.
  • Real-Time Feedback: Observe immediate updates to Viking Therapeutics’ valuation as you tweak inputs.
  • Preloaded Data: Comes with Viking Therapeutics’ actual financial metrics for swift evaluations.
  • Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Investors: Accurately estimate Viking Therapeutics, Inc.'s (VKTX) fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Viking Therapeutics, Inc. (VKTX).
  • Consultants: Quickly customize the template for valuation reports tailored to clients focused on Viking Therapeutics, Inc. (VKTX).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Viking Therapeutics, Inc. (VKTX).
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector, including Viking Therapeutics, Inc. (VKTX).

What the Template Contains

  • Historical Data: Includes Viking Therapeutics’ past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Viking Therapeutics’ intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Viking Therapeutics’ financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.